Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1

Cellular and Molecular Immunology

Volumn 10, Issue 2, 2013, Pages 176-182

  Sun, Jintang ^a   Feng, Alei ^a   Chen, Songyu ^a   Zhang, Yun ^a   Xie, Qi ^a   Yang, Meixiang ^a   Shao, Qianqian ^a   Liu, Jia ^a   Yang, Qifeng ^b   Kong, Beihua ^b   Qu, Xun ^a,b,c  

^a Basic Research Institute of Medical Sciences in Shandong   (China)

^b Department of Obstetrics and Gynecology ^*  (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

alternative activation of monocytes; immune escape; MCP 1; OPN transcripts; TGF 1

Indexed keywords

CD163 ANTIGEN; CD206 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; OSTEOPONTIN; RECOMBINANT CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; IMMUNE EVASION; MICE; MICE, NUDE; MONOCYTES; OSTEOPONTIN; RNA SPLICING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84874586111     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.67     Document Type: Article

References (31)

1. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998; 30-31: 92-102.
2. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118.
3. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345.
4. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-161.
5. Barraclough R, Chen HJ, Davies BR, Davies MP, Ke Y, Lloyd BH et al. Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 1998; 63: 273-294.
6. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14: 1581-1588.
7. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 2008; 272: 148-159.
8. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005; 26: 741-751.
9. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008; 29: 68-78.
10. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD41 T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008; 181: 7480-7488.
11. Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005; 106: 946-955.
12. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
13. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000; 68: 495-502.
14. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-5215.
15. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM. Human macrophages promote the motility and invasiveness of osteopontinknockdown tumor cells. Cancer Res 2007; 67: 5141-5147.
16. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006; 25: 2192-2202.
17. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122: 889-897.
18. Blasberg JD, Goparaju CM, Pass HI, Donington JS. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2010; 139: 1587-1593.
19. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de MelloKD et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011; 9: 280-293.
20. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P et al. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 2010; 5: e9633.
21. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
22. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727.
23. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
24. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612.
25. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40: 1660-1667.
26. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
27. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404: 407-411.
28. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
29. Zheng W, Li R, Pan H, He D, Xu R, Guo TB et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1957-1965.
30. Chellaiah MA, Biswas RS, Rittling SR, Denhardt DT, Hruska KA. Rhodependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem 2003; 278: 29086-29097.
31. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003; 14: 173-189.